BioCentury
ARTICLE | Clinical News

Ravicti glycerol phenylbutyrate regulatory update

December 7, 2015 8:00 AM UTC

The European Commission approved Ravicti glycerol phenylbutrate from Horizon to treat urea cycle disorders (UCDs) in patients ages >=2 months. In February 2013, FDA approved the pre-prodrug of phenyla...